DDInter690 DDInter1933
A clear, colorless liquid rapidly absorbed from the gastrointestinal tract and distributed throughout the body. It has bactericidal activity and is used often as a topical disinfectant. It is widely used as a solvent and preservative in pharmaceutical preparations as well as serving as the primary ingredient in alcoholic beverages.
Vigabatrin is an analog of gamma-aminobutyric acid ([GABA]), the main inhibitory neurotransmitter in the central nervous system, used in the treatment of refractory seizures and infantile spasms. It irreversibly inhibits the enzyme responsible for GABA metabolism, thereby increasing levels of circulating GABA. Although administered as a racemic mixture, only the S(+) enantiomer is pharmacologically active. It was first introduced as an antiepileptic agent in the United Kingdom in 1989 and was used extensively until 1997, when an association with vision loss became apparent. Its use is now generally reserved for patients who have failed alternative therapies, and its US approval by the FDA in 2009 mandated the creation of a drug registry to monitor patients for visual deficits.[L13661,A202124]
Ethanol {u} (Compound) binds {v} (Gene) CYP2B6
CYP2B6 {u} (Gene) is bound by {v} (Compound) Diphenhydramine
Diphenhydramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vigabatrin
Ethanol {u} (Compound) binds {v} (Gene) CYP4A11
CYP4A11 {u} (Gene) is bound by {v} (Compound) Dexamethasone
Dexamethasone {u} may lead to a major life threatening interaction when taken with {v} Vigabatrin
Ethanol {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Betamethasone
Betamethasone {u} may lead to a major life threatening interaction when taken with {v} Vigabatrin
Ethanol {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is associated with {v} (Disease) epilepsy syndrome
epilepsy syndrome {u} (Disease) is treated by {v} (Compound) Vigabatrin
Ethanol {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Alimemazine
Alimemazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vigabatrin
Ethanol {u} (Compound) binds {v} (Gene) GABRA1
GABRA1 {u} (Gene) interacts with {v} (Gene) GABBR1
GABBR1 {u} (Gene) is bound by {v} (Compound) Vigabatrin
Ethanol (Compound) binds CYP2B6 (Gene) and CYP2B6 (Gene) is bound by Diphenhydramine (Compound) and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Vigabatrin
Ethanol (Compound) binds CYP4A11 (Gene) and CYP4A11 (Gene) is bound by Dexamethasone (Compound) and Dexamethasone may lead to a major life threatening interaction when taken with Vigabatrin
Ethanol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Betamethasone (Compound) and Betamethasone may lead to a major life threatening interaction when taken with Vigabatrin
Ethanol (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is associated with epilepsy syndrome (Disease) and epilepsy syndrome (Disease) is treated by Vigabatrin (Compound)
Ethanol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Alimemazine (Compound) and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Vigabatrin
Ethanol (Compound) binds GABRA1 (Gene) and GABRA1 (Gene) interacts with GABBR1 (Gene) and GABBR1 (Gene) is bound by Vigabatrin (Compound)